Corcept Therapeutics DAZALS studie met CORT113176 (dazucorilant)
DAZALS:
A multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (DAZALS).
This phase II study is sponsored by Corcept Therapeutics and aims to evaluate the safety (side effects) and efficacy (benefits) of dazucorilant. Dazucorilant is a glucocorticoid receptor antagonist, which blocks the effects of cortisol. This study will determine whether dazucorilant can reduce the neurotoxic effects of cortisol activity, and whether ALS patients benefit by slowing functional decline.
The study drug is a softgel capsule (a total of 4 capsules of 75mg) swallowed whole daily around the same time, once a day with food and 240 ml of water. You have a 2 in 3 chance of getting the active study drug. (1/3 will receive a 150mg dose, 1/3 will receive a 300mg dose and 1/3 will receive a placebo).
The study will last approximately 1 year. Globally, 198 patients will be included.
More info about this study can be found on the website www.clinicaltrials.org:
https://clinicaltrials.gov/ct2/show/NCT05407324
Interested, or desire further information? Contact us at onderzoek@als.be
